What Is The Galleri Test and Should YOU Get One?
Longevity Medical Clinic has used the Galleri multi-cancer early detection blood test for nearly three years to help identify cancers early. The test detects signals from over 50 cancers with 99.5% specificity and is designed to complement—not replace—standard screenings.
Dr. Ummat discusses Longevity Medical Clinic’s use of the Galleri multi-cancer early detection test, which they’ve offered for nearly three years and used with over 200 patients. He interviews Arthur, a Medical Science Liaison with Galleri, who explains how the blood-based test screens for more than 50 types of cancer by analyzing methylation patterns in cell-free DNA.
Arthur shares that the test is primarily recommended annually for adults 50–79, though younger individuals may consider it based on personal and family risk factors. The test is meant to complement—not replace—standard cancer screenings like colonoscopies or mammograms, especially since over 70% of deadly cancers currently have no established screening guidelines.
He also notes the test’s high specificity (99.5%), meaning false positives are rare (about 0.5%), and a positive predictive value of roughly 43–44% in clinical studies. Galleri’s development is supported by extensive research, including more than 385,000 enrolled participants and large studies such as Pathfinder, CCG-A1, and ongoing trials with the UK’s National Health System.
Dr. Ummat concludes by emphasizing the importance of early detection in improving healthspan and lifespan—core goals at Longevity Medical Clinic.
